121 Diagnostic utility of molecular and imaging biomarkers 2 other inclusion and exclusion criteria FNAC sample RAS molecular technique TN; histological f/u available additional preoperative US-FNAC n.o.s. HRAS, KRAS, NRAS 2x PCR master mix TN; FNAC sample with adequate nucleic acids FNAC sample n.o.s. KRAS, NRAS PCR and direct sequencing TN; FNAC with sufficient epithelial cells and nucleic acids for molecular analysis; histological f/u available residual material from FNAC and needle washout HRAS, KRAS, NRAS miRInform® Thyroid Test suspicious TN >5mm, FNAC sample positive for thyroglobulin FNAC needle wash-out HRAS, KRAS, NRAS HRM analysis and direct sequencing TN; no Hürthle cell cytology; histological f/u available FNAC needle wash-out HRAS, KRAS, NRAS miRInform® Thyroid Test adult with TN ≥1cm; FNAC with sufficient nucleic acids for molecular analysis; correct specimen handling and shipping; no duplicate or contaminated specimen additional FNAC aspirate HRAS, KRAS, NRAS miRinform® Thyroid Test TN; BRAF mutation negative FNAC smears HRAS, KRAS, NRAS direct sequencing TN; air-dried FNAC slide available; histological f/u and FFPE samples available for mutation analysis air-dried FNAC smears HRAS, KRAS, NRAS HRM analysis for KRAS and NRAS, pyrosequencing for HRAS/ KRAS/NRAS TN n.o.s. air-dried FNAC smears HRAS, KRAS, NRAS PCR and pyrosequencing TN; sufficient DNA quality and quantity FNAC needle wash-out KRAS, NRAS pyrosequencing TN; sufficient nucleic acids for molecular analysis; histological f/u available residual material from two FNAC passes HRAS, KRAS, NRAS ThyroSeq® v2 TN; size >1cm; histological f/u available air-dried FNAC smears HRAS, KRAS, NRAS real-time PCR, HRM and pyrosequencing adults; TN; no history of radiation exposure; no family history of thyroid carcinoma; histological f/u available FNAC cell block HRAS, KRAS, NRAS PCR and pyrosequencing adult with solitary cold TN ≥10mm; suspicious on US; normal TSH and calcitonin; histologic f/u available representative archived FNAC slide HRAS, KRAS, NRAS direct sequencing TN; BRAF mutation negative, histological f/u available if RAS mutation detected or size >2cm or suspicious US features or resection upon patient request. FNAC slides HRAS, KRAS, NRAS PCR and pyrosequencing TN; sufficient DNA for molecular analysis; histological f/u available cell blocks, or FNAC smears if DNA from cell block <10 ng HRAS, KRAS, NRAS AmpliSeq™ Cancer Hotspot Panel v2 TN n.o.s. residual material from 1 or 2 FNAC passes HRAS, KRAS, NRAS ThyroSeq® v2.1 TN; suspicious US features; histological or cytological f/u available additional needle pass HRAS, KRAS, NRAS real-time PCR and HRM TN; suspicious on US; sufficient nucleic acids for mutation analysis; BRAF mutation negative; cytological or histological f/u available FNAC smears HRAS, KRAS, NRAS PCR and sequencing n.o.s. TN n.o.s. n.s. HRAS, KRAS, NRAS miRinform® Thyroid Test FFPE: formalin-fixed paraffin-embedded. FMCA: fluorescence melting curve analysis. f/u: follow-up. HRM: High resolution melting. ni: total number of indeterminate thyroid nodules included in our analysis. n.o.s.: not otherwise specified. n.s.: not specified. ntot: total number of thyroid nodules in study. PCR: polymerase chain reaction. PS: prospective. RS: retrospective. SHCN/HCN: cytology (suspicious for a) Hürthle cell neoplasm. TN: thyroid nodule.
RkJQdWJsaXNoZXIy MTk4NDMw